Genomics in Cancer Care Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Genomics in Cancer Care Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Instruments, Consumables, Services), By Technology (Genome Sequencing, PCR, Microarray, Nucleic Acid Extraction and Purification, Others), By Application (Diagnostics, Personalized Medicine, Drug Discovery & Development, Research), By End User (Hospitals, Research Institutes & Academic Institutes, Others), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Genomics in Cancer Care Market is projected for substantial growth, expanding from USD 16.79 Billion in 2025 to USD 42.94 Billion by 2031, at a robust 16.94% CAGR. This market focuses on analyzing patient and tumor genetic profiles to guide precision oncology through targeted therapies and personalized diagnostic strategies. Its expansion is fundamentally driven by the escalating global incidence of oncological diseases, demanding advanced diagnostic tools, alongside the continuous reduction in costs associated with next-generation sequencing (NGS) technologies. For instance, the American Cancer Society projects 2,041,910 new cancer cases in the United States in 2025, underscoring the critical need for genomic interventions. The declining costs of genome sequencing, propelled by advancements like the 352 NovaSeq X instruments shipped by Illumina in 2023, allow clinical laboratories to process samples more efficiently, thereby democratizing access to comprehensive genomic profiling. Complementing this, non-invasive liquid biopsy solutions are revolutionizing diagnostics by detecting circulating tumor DNA for early detection and monitoring, as demonstrated by Guardant Health's Shield test achieving 83% sensitivity for colorectal cancer detection. This accessibility is crucial given the World Health Organization's prediction of a 77% rise in new cancer cases to 35 million by 2050, highlighting the need for scalable screening tools.
Market Driver
The continuous reduction in genome sequencing costs, driven by advancements in Next-Generation Sequencing (NGS) technologies, serves as a primary engine for market growth by enabling high-throughput sequencing platforms to process genetic samples with greater speed and efficiency. This democratizes access to comprehensive genomic profiling, as evidenced by Illumina's shipment of 352 NovaSeq X instruments during 2023, which significantly scaled up genomic sequencing capabilities for laboratories and reduced the barrier to entry for healthcare facilities to integrate complex genomic data into routine oncology workflows. Simultaneously, the emergence of non-invasive liquid biopsy solutions is reshaping clinical diagnostics by offering a viable alternative to traditional tissue biopsies, detecting circulating tumor DNA to identify genetic mutations and facilitate early detection and continuous monitoring of treatment response. According to Guardant Health, its FDA-approved Shield test demonstrated 83% sensitivity for colorectal cancer detection. This shift toward accessible testing is crucial as the global burden of disease intensifies, with new cancer cases predicted to rise by 77% to reach 35 million by 2050, as reported by the World Health Organization in 2024. Consequently, the scalability of liquid biopsies directly addresses the need for mass screening tools capable of managing this increasing patient population.
Market Challenge
Despite this strong growth trajectory, the market faces significant impediments, primarily the lack of standardized reimbursement policies and the high costs associated with comprehensive genomic profiling. Inconsistent payer coverage criteria create financial uncertainty for healthcare providers, often leading to hesitation in ordering advanced diagnostic tests, which limits the generation of essential genetic data and disrupts clinical workflows. This economic burden extends directly to patients, with high out-of-pocket expenses often forcing them to decline recommended profiling, as exemplified by more than 40% of cancer patients in the United States exhausting their life savings within two years of treatment, according to the American Association for Cancer Research. Consequently, patient access and adoption rates are reduced, stifling market expansion and potential revenue growth for genomic interventions in standard cancer care.
Market Trends
The market is simultaneously being shaped by transformative trends. The integration of artificial intelligence (AI) into genomic workflows is automating the analysis of vast datasets to identify actionable oncological biomarkers, thereby addressing manual variant curation bottlenecks and allowing researchers to efficiently correlate complex genetic profiles with therapeutic outcomes. This commercial traction is significant as laboratories seek to scale precision oncology operations, with Tempus AI reporting full-year revenue of $693.4 million in 2024, representing a 30.4% year-over-year increase driven by the widespread adoption of its AI-enabled genomics platform, highlighting the growing reliance on computational tools for enhanced diagnostic speed and accuracy. Concurrently, the emergence of long-read sequencing technologies is proving essential for detecting complex structural variants often missed by traditional short-read platforms. These systems sequence long DNA stretches without fragmentation, providing a more complete picture of tumor heterogeneity and fusion genes critical for targeted treatment planning. The rapid adoption of this technology is evident in Oxford Nanopore Technologies' PromethION product range, which experienced a 55.8% year-over-year revenue growth in 2024, indicating a strong market shift toward native long-read capabilities that empower clinicians to uncover comprehensive structural data vital for developing novel cancer therapies.
Key Market Players
* Illumina Inc
* Agilent Technologies, Inc.
* Roche Diagnostics
* Cancer Genetics, Inc.
* Bio-Rad Laboratories Inc
* Sigma-Aldrich Corp
* QIAGEN NV
* GE Healthcare Inc
* Life Technologies Corp
* Quest Diagnostics Inc
Report Scope
In this report, the Global Genomics in Cancer Care Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Genomics in Cancer Care Market, By Product
* Instruments
* Consumables
* Services
# Genomics in Cancer Care Market, By Technology
* Genome Sequencing
* PCR
* Microarray
* Nucleic Acid Extraction and Purification
* Others
# Genomics in Cancer Care Market, By Application
* Diagnostics
* Personalized Medicine
* Drug Discovery & Development
* Research
# Genomics in Cancer Care Market, By End User
* Hospitals
* Research Institutes & Academic Institutes
* Others
# Genomics in Cancer Care Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Genomics in Cancer Care Market.
Available Customizations:
Global Genomics in Cancer Care Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Genomics in Cancer Care Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Instruments, Consumables, Services)
5.2.2. By Technology (Genome Sequencing, PCR, Microarray, Nucleic Acid Extraction and Purification, Others)
5.2.3. By Application (Diagnostics, Personalized Medicine, Drug Discovery & Development, Research)
5.2.4. By End User (Hospitals, Research Institutes & Academic Institutes, Others)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. North America Genomics in Cancer Care Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Technology
6.2.3. By Application
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Genomics in Cancer Care Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Technology
6.3.1.2.3. By Application
6.3.1.2.4. By End User
6.3.2. Canada Genomics in Cancer Care Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Technology
6.3.2.2.3. By Application
6.3.2.2.4. By End User
6.3.3. Mexico Genomics in Cancer Care Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Technology
6.3.3.2.3. By Application
6.3.3.2.4. By End User
7. Europe Genomics in Cancer Care Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Technology
7.2.3. By Application
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Genomics in Cancer Care Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Technology
7.3.1.2.3. By Application
7.3.1.2.4. By End User
7.3.2. France Genomics in Cancer Care Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Technology
7.3.2.2.3. By Application
7.3.2.2.4. By End User
7.3.3. United Kingdom Genomics in Cancer Care Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Technology
7.3.3.2.3. By Application
7.3.3.2.4. By End User
7.3.4. Italy Genomics in Cancer Care Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Technology
7.3.4.2.3. By Application
7.3.4.2.4. By End User
7.3.5. Spain Genomics in Cancer Care Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Technology
7.3.5.2.3. By Application
7.3.5.2.4. By End User
8. Asia Pacific Genomics in Cancer Care Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Technology
8.2.3. By Application
8.2.4. By End User
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Genomics in Cancer Care Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Technology
8.3.1.2.3. By Application
8.3.1.2.4. By End User
8.3.2. India Genomics in Cancer Care Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Technology
8.3.2.2.3. By Application
8.3.2.2.4. By End User
8.3.3. Japan Genomics in Cancer Care Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Technology
8.3.3.2.3. By Application
8.3.3.2.4. By End User
8.3.4. South Korea Genomics in Cancer Care Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Technology
8.3.4.2.3. By Application
8.3.4.2.4. By End User
8.3.5. Australia Genomics in Cancer Care Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Technology
8.3.5.2.3. By Application
8.3.5.2.4. By End User
9. Middle East & Africa Genomics in Cancer Care Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Technology
9.2.3. By Application
9.2.4. By End User
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Genomics in Cancer Care Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Technology
9.3.1.2.3. By Application
9.3.1.2.4. By End User
9.3.2. UAE Genomics in Cancer Care Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Technology
9.3.2.2.3. By Application
9.3.2.2.4. By End User
9.3.3. South Africa Genomics in Cancer Care Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Technology
9.3.3.2.3. By Application
9.3.3.2.4. By End User
10. South America Genomics in Cancer Care Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Technology
10.2.3. By Application
10.2.4. By End User
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Genomics in Cancer Care Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Technology
10.3.1.2.3. By Application
10.3.1.2.4. By End User
10.3.2. Colombia Genomics in Cancer Care Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Technology
10.3.2.2.3. By Application
10.3.2.2.4. By End User
10.3.3. Argentina Genomics in Cancer Care Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Technology
10.3.3.2.3. By Application
10.3.3.2.4. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Genomics in Cancer Care Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Illumina Inc
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Agilent Technologies, Inc.
15.3. Roche Diagnostics
15.4. Cancer Genetics, Inc.
15.5. Bio-Rad Laboratories Inc
15.6. Sigma-Aldrich Corp
15.7. QIAGEN NV
15.8. GE Healthcare Inc
15.9. Life Technologies Corp
15.10. Quest Diagnostics Inc
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們